NCT00178932Completed
Improving Outcome in Schizophrenia Through Identification of Genetic Risk Factors
Source: ClinicalTrials.gov · Last updated 18 Mar 2025
Brief summary (registry, in English)
The goals of this study are to replicate previous findings of genetic predictors of response to clozapine and other antipsychotic drugs.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 37 (actual)
- First submitted
- 12 Sept 2005
- Start date
- Nov 1998
- Primary completion date
- 16 May 2024
- Lead sponsor
- Northwestern University
- Diseases
- Schizophrenia, Depression, Bipolar disorder
- NCT number
- NCT00178932
What you commit to
- Study type: Interventional
- Participants enrolled: 37
- From Nov 1998 to the primary completion date, 16 May 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with DSM-IV diagnoses other than schizophrenia or schizoaffective disorder, and bipolar disorder or major depression with psychotic features.
Who the study is looking for
- Patients with the diagnoses of schizophrenia or schizoaffective disorder, and bipolar disorder or major depression with psychotic features, or volunteers with no history of a psychotic disorder.
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Psychiatric Hospital at Vanderbilt Coordinator of this site? Confirm its status | Nashville | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.